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Abstract
Introduction: HPTN 071 (PopART) is a three-arm community randomized trial in Zambia and South Africa evaluating the
impact of a combination HIV prevention package, including universal test and treat (UTT), on HIV incidence. This nested study
examined factors associated with timely linkage-to-care and ART initiation (TLA) (i.e. within six-months of referral) in the con-
text of UTT within the intervention communities of the HPTN 071 (PopART) trial.
Methods: Of the 7572 individuals identified as persons living with HIV (PLWH) (and not on antiretroviral treatment (ART))
during the first year of the PopART intervention provided by Community HIV-care Providers (CHiPs) through door-to-door
household visits, individuals who achieved TLA (controls) and those who did not (cases), stratified by gender and community,
were randomly selected to be re-contacted for interview. Standardized questionnaires were administered to explore factors
potentially associated with TLA, including demographic and behavioural characteristics, and participants’ opinions on HIV and
related services. Odds ratios comparing cases and controls were estimated using a multi-variable logistic regression.
Results: Data from 705 participants (333 cases/372 controls) were analysed. There were negligible differences between cases
and controls by demographic characteristics including age, marital or socio-economic position. Prior familiarity with the CHiPs
encouraged TLA (aOR of being a case: 0.58, 95% CI: 0.39 to 0.86, p = 0.006). Participants who found clinics overcrowded (aOR:
1.51, 95% CI: 1.08 to 2.12, p = 0.006) or opening hours inconvenient (aOR: 1.63, 95% CI: 1.06 to 2.51, p = 0.02) were less likely
to achieve TLA, as were those expressing stronger feelings of shame about having HIV (ptrend = 0.007). Expressing “not feeling
ready” (aOR: 2.75, 95% CI: 1.89 to 4.01, p < 0.001) and preferring to wait until they felt sick (aOR: 2.00, 95% CI: 1.27 to 3.14,
p = 0.02) were similarly indicative of being a case. Worrying about being seen in the clinic or about how staff treated patients was
not associated with TLA.While the association was not strong, we found that the greater the number of self-reported lifetime sex-
ual partners the more likely participants were to achieve TLA (ptrend = 0.06). There was some evidence that participants with
HIV-positive partners on ARTwere less likely to be cases (aOR: 0.75, 95% CI: 0.53 to 1.06, p = 0.07).
Discussion: The lack of socio-demographic differences between cases and controls is encouraging for a “universal” interven-
tion that seeks to ensure high coverage across whole communities. Making clinics more “patient-friendly” could enhance treat-
ment uptake further. The finding that those with higher risk behaviour are more actively engaging with UTT holds promise for
treatment-as-prevention.
Keywords: linkage to care; ART initiation; cascade of care; differentiated care; universal test and treat; universal treatment;
immediate ART; treatment as prevention
Additional Supporting Information may be found online in the Supporting information tab for this article.
Received 22 June 2017; Accepted 27 November 2017
Copyright © 2017 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an
open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
1 | INTRODUCTION
The concept of universal test and treat (UTT) has been widely
promoted for approximately the last decade, and definitive
evidence for the efficacy of treatment as prevention at the
level of individual partnerships has been available since the
results of the HPTN (HIV Prevention Trials Network) 052 trial
were announced in 2011 [1,2]. Other studies have since
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provided clear evidence on the benefits of early treatment for
the health of the person living with HIV (PLWH) [3,4]. The
World Health Organization (WHO) has revised its guidelines,
to recommend that all PLWH be offered antiretroviral treat-
ment (ART) irrespective of CD4 count, also known as “imme-
diate treatment” [5].
The HPTN 071 (Population Effects of Antiretroviral Ther-
apy to Reduce HIV Transmission (PopART)) trial has been
underway in 21 communities in Zambia and South Africa to
examine the impact of a combination prevention package
including UTT on HIV-incidence at a community level. The trial
consists of three arms as described elsewhere [6] and illus-
trated in Figure 1, and the full intervention arm (Arm A) has
offered UTT from the launch of the trial in 2014. Data from
the first year of delivering the intervention in Zambia indicate
that among PLWH an estimated 78% of men and 87% of
women were aware of their HIV-positive status and approxi-
mately three-quarters of them were on ART after one year
[7].
In order for UTT to have maximal impact in reducing
community-level HIV-incidence, uptake of treatment would
have to be wide-spread across subsets of the population
with different socio-demographic and behavioural character-
istics. There is evidence on factors associated with initiation
of ART, usually among individuals who have already linked-
to-care at least once since HIV diagnosis and from contexts
where ART eligibility criteria applied [8-13]. More scarce
are data from settings providing immediate treatment or
UTT, with the latter not only making ART immediately avail-
able for all who have already presented to health-facilities,
but first seeking to test everyone in the community (univer-
sal testing) [14]. Although a UTT approach substantially sim-
plifies treatment by removing ART initiation criteria,
providers must still negotiate all the steps along the cascade
of care, to link clients to care following HIV detection in
the community and achieve timely initiation of ART. Evi-
dence from the ANRS TasP trial indicates that linkage-to-
care is a major barrier to achieving high treatment coverage
[15]. UTT also involves attempting to initiate treatment in a
timely fashion, in individuals who were diagnosed as part of
a universal testing programme in the community, who may
not otherwise have sought to find out their HIV status.
While this helps achieve universal knowledge of HIV status
and identify as many PLWH as possible, it may also pose
challenges for treatment readiness in addition to other
potential barriers.
The study described here examined the factors associated
with the uptake of universal treatment, specifically timely link-
age-to-care and initiation of treatment (which we will refer to
as timely linkage-to-ART (TLA)) following door-to-door univer-
sal testing, during the first year of the PopART UTT interven-
tion. The study objectives were to identify differences
between those who had not achieved TLA (cases) and those
who had done so (controls). TLA was defined as linkage-to-
care and initiation of ART within six months of referral by
Community HIV-care Providers (CHiPs).
3 arm cluster-randomised trial with 21 communies 
Full PopART
intervenon 
including
immediate ART 
irrespecve of CD4 
count
Standard of care at 
current service 
provision levels 
including 
ART iniaon 
according to current 
naonal guidelines
ART iniaon 
according to current 
naonal guidelines
7 communies 
per arm (N = 21)Arm A Arm B Arm C
PopART intervenon 
except
PopART intervention package
Annual rounds of  Home Based Voluntary HIV Testing by Community HIV-care Providers (CHiPs)
Health promotion, Active Referral and/or Retention in Care support by CHiPs for the following:
• Voluntary Medical Male Circumcision (VMMC) for HIV negative men
• Prevention of Mother to Child Transmission (PMCT) for HIV positive women
• HIV treatment and care for all HIV positive individuals
• Promotion of sexual health and TB services
• Condom provision
ART irrespective of CD4-count or immune-status provided at the local health centre in Arm A 
~ 2,000 random sample 
from each community :
Populaon Cohort 
N = 42,000
Primary outcome:
HIV incidence at 36 months
12 in Zambia
9 in S. Africa
Figure 1. Overview of the HPTN 071 (PopART) trial.
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2 | METHODS
The nested case-control study was carried out in PopART
Arm A communities which offered UTT: four in Zambia and
three in South Africa (Figure 1). CHiPs (lay counsellors
employed and trained to work in their own communities), pro-
vided a door-to-door community-based package of services
(Figure 1) and captured the details of all individuals who con-
sented to the PopART intervention on an electronic register
[6]. During the initial CHiP home visit, HIV was detected
through HIV testing and counselling (HTC) or by individuals
self-reporting HIV-positive status. All PLWH who were not on
ART were offered referral to the local health-facility for link-
age-to-ART. Follow-up home visits were conducted to ascer-
tain linkage and ART initiation outcomes and recorded in the
CHiP electronic register.
Community members who were referred between January
2014 and January 2015, during the first year of the PopART
intervention and had had at least six months to achieve TLA
(by July 2015) were eligible for the case-control study. Fur-
thermore, participants had to be ≥18 years old and be able
and willing to provide informed consent.
The data on TLA entered into the database at a follow-up
home visit by CHiPs, more than six months after referral (to
allow time for TLA), were used as a starting point for random
selection of study participants. Participants who had achieved
TLA within six months of referral by CHiPs were eligible to
be controls; individuals who had been followed up after six
months but had not started ART at all or only started after
six months were potential cases. From all those who were eli-
gible to be cases in the database, approximately 140 potential
cases per community (50% men and 50% women) were ran-
domly selected. These were placed in a random order (strati-
fied by community and gender), on a sequential list of
potential subjects. An equal number of gender-matched indi-
viduals per community, who did manage TLA (controls) were
then randomly selected in the same way. A sample in excess
of the number required for recruitment (approximately 60
cases and 60 controls per community, stratified by gender)
was selected in anticipation of difficulties in finding partici-
pants, given the mobility and migration in the study communi-
ties. Due to a wide range in community sizes, the numbers of
individuals meeting the case and control definition varied
across communities and some communities had fewer individ-
uals than required by the study while others had much larger
numbers. This meant that in the smaller communities every-
one who had been referred was selected, rather than a ran-
dom subset.
Verbal permission to allow case-control (CC) field research
assistants (RAs) to approach participants was obtained by the
CHiP staff who had previously referred individual community
members for TLA. Written informed consent for study partici-
pation was then obtained by CC study RAs. RAs conducted
electronically administered surveys with standardized ques-
tionnaires. Questionnaire themes were informed by current
evidence in the literature and anecdotal local information on
factors that may influence TLA. Participants’ case or control
status was not given to RAs.
The final sample size of approximately 700 participants (1:1
case:control ratio) provided just over 80% study power to
detect associations with odds ratios of approximately 1.75 or
higher (or approximately 0.5 or lower), for explanatory vari-
ables with 15% prevalence in controls (a = 0.05). Odds ratios
were estimated using a multivariable logistic regression and
all models included community and gender to account for the
frequency-matched sampling strategy. Age category was then
included as an a priori potentially confounding variable. Addi-
tional variables which showed at least weak evidence of asso-
ciation with TLA were included as appropriate. Likelihood
ratio testing (LRT) was done to assess the statistical evidence
of association. Evidence of interaction with gender and coun-
try was explored. For variables with three or more response
categories and potential for a dose-response relationship,
tests for trend were performed.
The study was approved by the ethics committees of the
University of Zambia, Stellenbosch University and London
School of Hygiene and Tropical Medicine.
3 | RESULTS
3.1 | Demographic, sexual behaviour and health-
related characteristics
During the first year of the PopART intervention 152,383
individuals consented to participate in the PopART interven-
tion in the 7 arm A communities. Of these, 11% (n = 16,112
individuals) were identified as living with HIV (newly diag-
nosed or self-report of known HIV-positive status) and 7572
were referred to HIV care, among those not on ART at the
time of referral. After allowing at least six months for TLA,
68% (n = 5161) were documented as either having started
ART within six months after referral, or were followed up
>6 months after referral and had not started ART. Of these,
47% (n = 2444 individuals) had linked-to-care and initiated
ART within six months of referral and 53% (n = 2717) had
not.
Of the 2717 potential cases who did not achieve TLA, 908
were randomly selected to be contacted by CHiPs, and 437
(48%) were found and agreed to be contacted by the CC field
RAs. Of them, 333 (76%) cases consented to participate in
the study (Figure 2a). Of the 812 potential controls who
achieved TLA and were randomly selected, 460 (57%) agreed
to be contacted by the CC RAs and a slightly greater propor-
tion were successfully recruited (372 (81%)) (Figure 2b).
Data from 705 participants were included in the final analy-
sis: 79% (555) from four communities in Zambia and 21% (150)
from three communities in South Africa. There were fewer men
(approximately 40%) than women (approximately 60%) in the
study, but proportions were balanced by case/control status
(Table 1). When compared with the randomly selected sample,
there was a lower proportion of 18 to 24 year olds in the final
study population (10% in the final study sample vs. 18% in the
randomly selected sample of both cases and controls) and a
higher proportion of ≥45 year olds (22% vs. 11% among cases,
and 25% vs. 15% among controls).
Most participants were married, had had primary education
only and were unemployed (2% of all participants were stu-
dents). There were no differences by case/control status for
any of these demographic characteristics, overall.
The majority of participants reported two to five lifetime
sexual partners and the number of partners was associated
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with case/control status. There is a suggestion of a trend that
the greater the number of partners the more likely partici-
pants were to achieve TLA (with diminishing odds ratios
(aORs) of being a case, ptrend = 0.06) (Table 1).
The HIV and ART status of the participant’s main partner
(of the last 12 months) was associated with case/control sta-
tus. Compared to those who did not report having a known
HIV-positive partner, participants who had HIV-positive part-
ners not on ART (although there were relatively few in that
category) were twice as likely to be cases themselves (aOR:
2.02, 95% CI: 1.11 to 3.66, p = 0.02). Participants whose HIV-
positive partners were on ART were less likely to be cases
(OR: 0.70, 95% CI: 0.50 to 0.98, p = 0.04), but the evidence
of association was weaker in the adjusted model (aOR: 0.75,
95% CI: 0.53 to 1.06, p = 0.07).
Participants who had previously linked-to-care (prior to
CHiP referral) and were still in care (but not on ART) when
the initial CHiP home visit was conducted were less likely to
be cases than those who had never previously linked (aOR:
0.60, 95% CI: 0.38 to 0.96, p = 0.03). Although there were
relatively few participants who reported that they had previ-
ously linked but had defaulted from care, when compared
against those who had never linked there was no evidence of
a difference (aOR: 0.79, 95% CI: 0.42 to 1.47, p = 0.45)
(Table 1). There was no relationship between latest CD4-
count (self-reported at the time of the CC study by those
who had had it done) and case/control status. However, not
having had a CD4-count done or not knowing one’s result was
predictive of being a case (aOR: 1.94, 95% CI: 1.18 to 3.21,
p = 0.009) when compared with those who had a CD4-count
which was low (0 to 350/cm3).
3.2 | Participants’ perceptions of HIV service
factors which may affect TLA
Cases and controls were asked (identical) standardized ques-
tions about factors that encourage TLA (regardless of whether
TLA was achieved). Prior familiarity with the CHiP who deliv-
ered the intervention encouraged TLA (aOR of being a case:
0.58, 95% CI: 0.39 to 0.86, p = 0.006) (Table 2). The majority
of participants accepted HIV testing with the CHiP, and this
appears to be associated with being a case, although not
reaching statistical significance in the adjusted model (aOR:
1.60, 95% CI: 0.95 to 2.70, p = 0.07) when compared with
individuals who self-reported HIV-positive status.
Participants who reported time constraints due to work or
housework as a factor which discouraged linkage-to-care were
more likely to be cases (aOR: 1.64, 95% CI: 1.14 to 2.38,
p = 0.02). When restricted to those who had not previously
linked-to-care prior to the CHiP referral (N = 603), a number
of factors related to accessing the clinic, including inconve-
nient clinic opening hours (aOR: 1.63, 95% CI: 1.06 to 2.51,
p = 0.02); overcrowding in the clinic (aOR: 1.51, 95% CI: 1.08
to 2.12, p = 0.006); and distance/time to travel to clinic (aOR:
2.55, 95% CI: 1.14 to 5.69, p = 0.009) were associated with
being a case (although very few complained of the latter in
the urban and peri-urban settings that characterize all our
communities) (Table 2). Expressing “not feeling ready” (aOR:
2.75, 95% CI: 1.89 to 4.01, p < 0.001) and preferring to wait
until they felt sick (aOR: 2.00, 95% CI: 1.27 to 3.14,
p = 0.02) were similarly indicative of being a case. Neither
being worried about being seen in the clinic or perceptions
about how staff treated patients was associated with TLA
(data not shown).
3.3 | Perceived advantages and disadvantages to
the individual of achieving TLA (including stigmatizing
attitudes)
Participants who said that they would start ART for their own
health, even without feeling unwell, were more likely to
achieve TLA (aOR of being a case: 0.53, 95% CI: 0.38 to 0.75,
p < 0.001) as were those who said they would comply with
CHiPs/clinic staff’s advice to link-to-ART without delay (aOR
of being a case: 0.56, 95% CI: 0.34 to 0.91, p = 0.02). There
was weak evidence that knowing others who were well on
ART (aOR: 0.74, 95% CI: 0.53 to 1.03, p = 0.08) encouraged
TLA. There was no strong association between case/control
status and stating that protecting a partner from acquiring
HIV was a factor which encouraged TLA (aOR: 0.81, 95% CI:
0.58 to 1.12, p = 0.19) (Table 3).
As was seen with “not feeling ready” to link to care
(Table 2), “not feeling ready” to take ART was also associated
with being a case (aOR: 2.25, 95% CI: 1.58 to 3.21,
p < 0.001). The idea of taking life-long treatment also
appeared to be a deterrent to TLA (aOR: 1.44, 95% CI: 1.00
to 2.07, p = 0.05) (Table 3).
Stigmatizing attitudes were not generally seen to affect TLA
(Table 3 and other data not shown). However, the more
strongly participants agreed with a statement about feeling
CHiPs attempted contact with 908 individuals who did not achieve TLA, 
randomly selected from CHiP data-base from the first annual round of HBT in PopART
(Zambia: 628/280 SA 1:)
RAs attempted contact with 437 (48%) potential cases to obtain informed 
consent to participate in CC study
(Zambia: 321/SA: 116)
471 (52%) individuals could not be located 
or declined to be contacted by CC team
(Zambia: 307/SA: 164)
333 (76%) cases in study sample
(Zambia: 258/75 SA: )
Usually 3 attempts made to locate 
individual if not initially found
Usually 3 attempts made to locate 
individual if not initially found
104 (24%) individuals could not be located, 
declined participation or were ineligible for the study
(Zambia: 63/SA: 41)
1. SA = South Africa
CHiPs attempt contacted with 812 individuals who achieved TLA, 
randomly selected from CHiP data-base from the first annual round of HBT in PopART
(Zambia: 616/SA 1: 196)
RAs attempted contact with 460 (57%) potential controls to obtain 
informed consent to participate in CC study
(Zambia: 352 /SA: 108)
352 (43%) individuals could not be located or 
declined to be contacted by CC team
(Zambia: 264/SA: 88)
372 (81%) controls in initial study sample
(Zambia: 297/SA: 75)
Usually 3 attempts made to locate 
individual if not initially found
Usually 3 attempts made to locate 
individual if not initially found
88 (19%) individuals could not be located, 
declined participation or were ineligible for the study
(Zambia: 55/SA: 33)
Figure 2. Case and control selection process.
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Table 1. Demographic, sexual behaviour and health-related characteristics of cases and controls
Controls
(achieved
TLA)
N (%)
Cases
(did not achieve
TLA) N (%)
Odds
ratioa
LRTb p-value,
95% confidence
interval
Adjusted
odds ratioc
LRTb p-value,
95% confidence
interval
Total
Genderd
Male 151 (41) 132 (40)
Female 220 (59) 201 (60)
Demographic and socio-economic characteristics
Age category
18 to 24 years 36 (10) 32 (10) 1 0.86 1 0.60
25 to 34 years 129 (35) 118 (35) 1.04 0.60 to 1.80 1.05 0.59 to 1.89
35 to 44 years 115 (31) 110 (33) 1.08 0.61 to 1.89 1.08 0.60 to 1.95
≥45 years 92 (25) 73 (22) 0.91 0.50 to 1.63 0.82 0.45 to 1.52
Marital status
Never married 48 (13) 55 (16) 1 0.48 1 0.27
Currently married 215 (58) 184 (55) 0.75 0.46 to 1.21 0.77 0.45 to 1.32
Previously marriede 109 (29) 94 (28) 0.75 0.44 to 1.28 0.63 0.35 to 1.12
Educational attainment ptrend 0.11
f
Primary (Grade 0 to 7) 183 (49) 153 (46) 1 0.76 1 0.21
Junior secondary (Grade 8 to 9) 94 (25) 84 (25) 1.09 0.75 to 1.58 1.15 0.77 to 1.72
Senior secondary (Grade 10
to 12)/higher education
94 (25) 96 (29) 1.22 0.83 to 1.78 1.45 0.96 to 2.19
Employment
None 181 (49) 166 (50) 1 0.42 1 0.41
Casual/seasonal/occasional 61 (16) 60 (18) 1.12 0.71 to 1.75 1.18 0.74 to 1.89
Self employed 67 (18) 64 (19) 1.12 0.73 to 1.73 1.22 0.77 to 1.92
Formal wage 63 (17) 43 (13) 0.75 0.47 to 1.19 0.79 0.49 to 1.29
SES (PCAg of HH factors & assetsh)
Lower 181 (49) 176 (53) 1 0.27 1 0.43
Higher 191 (51) 157 (47) 0.84 0.61 to 1.15 0.87 0.63 to 1.22
Sexual behaviour
No of lifetime sexual partners ptrend 0.06
f
1 33 (9) 47 (14) 1 0.02 1 0.04
2 to 5 221 (60) 192 (58) 0.57 0.34 to 0.93 0.55 0.33 to 0.92
6 to 9 49 (13) 48 (14) 0.59 0.30 to 1.13 0.56 0.28 to 1.10
≥10 68 (18) 45 (14) 0.40 0.21 to 0.75 0.38 0.19 to 0.74
Self-assessment of sexual risk (“My sexual behaviour (incl. partner(s) I have had), has put me at risk of getting HIV”)
Low 180 (49) 181 (55) 1 0.08 1 0.13
High 191 (51) 151 (45) 0.75 0.55 to 1.03 0.77 0.55 to 1.08
HIV and health factors
Has HIV status been disclosed to anyone
N 38 (10) 74 (22) 1 <0.001 1 <0.001
Y 334 (90) 259 (78) 0.39 0.25 to 0.59 0.39 0.25 to 0.60
HIV & ART status of spouse/main partneri (in last 12 m)
No sexual partner in last
12 m/partner HIV status not
known or reported HIV
negative
214 (58) 204 (61) 1 0.002 1 0.005
HIV positive partner not on
ART
20 (5) 37 (11) 1.96 1.10 to 3.49 2.02 1.11 to 3.66
HIV positive partner on ART 138 (37) 92 (28) 0.70 0.50 to 0.98 0.72 0.51 to 1.03
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ashamed because they were HIV-positive, the more likely they
were to be a case (test for trend p = 0.007).
3.4 | Differences in association by gender and
country
There was no statistical evidence of differences in association by
country but shown in Table S1 are associations which were seen
to differ by gender. While there was no association between edu-
cation of participants overall and of women alone with case/con-
trol status, men who had secondary education appeared more
likely to be cases than men with primary education (aOR: 2.50,
95% CI: 1.30 to 4.82, p = 0.02). However, there was no clear
trend seen across educational strata. Amongst men but not
amongst women, being familiar with the CHiP prior to the initial
PopART home visit was strongly associated with TLA (aOR of
being a case among men: 0.29, 95% CI: 0.14 to 0.58, p < 0.001).
The majority of participants irrespective of gender or case/
control status had disclosed their HIV status to someone.
Among women, there was statistical evidence of disclosure
encouraging TLA (aOR of being a case: 0.18, 95% CI: 0.09 to
0.36, p < 0.001) while the association was weak among men.
Men who had a high AUDIT (Alcohol Use Disorders Identifica-
tion Test) score (≥8) which denoted hazardous and harmful
alcohol use [16], and possible dependence, were more likely
to be cases (aOR: 2.13, 95% CI: 1.20 to 3.81, p = 0.009) than
men with lower scores (≤7), while this was not the case
among women who drank excessively.
4 | DISCUSSION
This study examined factors associated with the timely initia-
tion of ART in high HIV prevalence settings in sub-Saharan
Table 1. (Continued)
Controls
(achieved
TLA)
N (%)
Cases
(did not achieve
TLA) N (%)
Odds
ratioa
LRTb p-value,
95% confidence
interval
Adjusted
odds ratioc
LRTb p-value,
95% confidence
interval
Had participant linked to care prior to referral by CHiP
Not linked prior to CHiP 280 (75) 274 (82) 1 0.04 1 0.09
Linked prior to CHiP but not in
care when referred
29 (8) 21 (6) 0.70 0.38 to 1.28 0.79 0.42 to 1.47
Linked prior to CHiP and in
care when referred (not self-
reported on ART)
63 (17) 38 (11) 0.59 0.38 to 0.92 0.60 0.38 to 0.96
Most recent CD4-count
0 to 350 60 (16) 34 (10) 1 <0.001 1 <0.001
351 to 500 44 (12) 18 (5) 0.72 0.36 to 1.46 0.69 0.33 to 1.43
≥501 53 (14) 34 (10) 1.17 0.63 to 2.16 1.17 0.62 to 2.20
Not done/don’t know CD4-
count
215 (58) 247 (74) 2.21 1.37 to 3.58 1.94 1.18 to 3.21
Health in last 12 m
Not been unwell 269 (72) 225 (68) 1 0.33 1 0.18
Unwell, not hospitalized 63 (17) 71 (21) 1.35 0.91 to 2.04 1.46 0.97 to 2.21
Unwell and hospitalized 40 (11) 37 (11) 1.07 0.66 to 1.74 1.19 0.72 to 1.99
AUDIT score
Audit score ≤7 253 (68) 226 (68) 1 0.85 1 0.73
Audit score ≥8 119 (32) 107 (32) 1.03 0.73 to 1.45 1.07 0.74 to 1.54
Values in italics are p-values, values in bold (with or without italics) indicate statistically significant values.
aA priori adjusted for gender and community to reflect sampling strategy.
bLikelihood ratio test.
cMultivariable model a priori including gender, community, age category as well as demographic/behavioural factors which were associated with
case/control status (i.e. whether CHiP was known to participant prior to PopART to home-visit, whether HIV status has been disclosed, whether
partner is HIV positive and on ART, and lifetime number of sexual partners).
dOne participant (control) with missing gender data.
ePreviously married = separated/divorced/widowed.
fp-value for test for tend.
gPrincipal components analysis.
hHH factors detailed house structure, water, sanitation, electricity and cooking fuel used; assets listed were: working cell-phone, bicycle, motorcy-
cle or scooter, car/bakkie, electricity to house, television set, fridge/freezer, radio, computer/laptop, CD or MP3 player, stereo/cassette/other music
player, “none of the above.”
iParticipant’s own definition of “main partner.”
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Africa, in greater detail than any other published study we are
aware of. It provides novel insights into TLA in the context of
UTT, with participants identified with HIV during universal
door-to-door home-based HIV testing. We have examined the
combined outcome of TLA which requires linkage-to-care fol-
lowing HIV detection and referral in the community, and initia-
tion of ART in the health facility, all within a relatively short
period (six months). The predictors of TLA we have examined
may have influenced either linkage to care or ART initiation or
both. Only one other study we are aware of has examined fac-
tors associated with “linkage-to-ART” [17]. Other studies have
focused instead either on predictors of linkage-to-care or on
predictors of initiation of ART among those already linked-to-
care or diagnosed in health facilities. Yet, as community-based
HIV testing becomes widespread in high HIV prevalence set-
tings, combined with immediate eligibility for ART, we consider
Table 2. Participants perceptions of HIV service factors which may affect initiation of timely treatment
Controls
(achieved TLA)
N (%)
Cases (did not
achieve TLA) N (%)
Odds
ratioa
LRTb p-value,
95% confidence
interval
Adjusted
odds ratioc
LRTb p-value, 95%
confidence interval
CHiP related factors
Was the CHiP previously known to participant (prior to PopART home-visit)
N 259 (70) 253 (76) 1 0.05 1 0.006
Y 113 (30) 80 (24) 0.70 0.48 to 1.01 0.58 0.39 to 0.86
Did participant have an HIV test with CHiPd
N 47 (13) 27 (8) 1 0.05 1 0.07
Y 325 (87) 306 (92) 1.63 0.99 to 2.71 1.60 0.95 to 2.70
Was the CHiP someone you could talk to openly? ptrend 0.01
e
Strongly disagree/Disagree 7 (2) 14 (4) 1 0.02 1 0.04
Agree 66 (18) 80 (24) 0.59 0.22 to 1.58 0.64 0.23 to 1.81
Strongly agree 299 (80) 239 (72) 0.37 0.14 to 0.97 0.41 0.15 to 1.13
Factors specifically affecting linkage to care
Time constraints affecting linkage to care
Already in care/time not a constraint
for LTC
289 (78) 231 (69) 1 0.02 1 0.02
Time constraints due to livelihood/
housework or both
82 (22) 102 (31) 1.62 1.14 to 2.30 1.64 1.14 to 2.38
Among those never previously registered for care prior to CHiP referral (N = 603), did the following affect linkage to care?
“Clinic is only open when I am at work”
N 262 (85) 231 (78) 1 0.03 1 0.02
Y 46 (15) 64 (22) 1.63 1.06 to 2.51 1.63 1.06 to 2.51
“Clinic is too crowded”
N 181 (59) 144 (49) 1 0.12 1 0.006
Y 127 (41) 151 (51) 1.50 1.07 to 2.11 1.51 1.08 to 2.12
“I could not go to the clinic because it is too far away/because of the time it would take to travel there”
N 299 (97) 273 (93) 1 0.02 1 0.03
Y 9 (3) 22 (7) 2.52 1.13 to 5.61 2.55 1.14 to 5.69
“I am not ready to go the clinic for HIV care”
N 249 (81) 183 (62) 1 <0.001 1 <0.001
Y 59 (19) 112 (38) 2.68 1.84 to 3.89 2.75 1.89 to 4.01
“I will only go if/when I feel sick”
N 270 (88) 232 (79) 1 0.003 1 0.02
Y 38 (12) 63 (21) 1.96 1.26 to 3.07 2.00 1.27 to 3.14
Values in italics are p-values, values in bold (with or without italics) indicate statistically significant values.
aA priori adjusted for gender and community to reflect sampling strategy.
bLikelihood ratio test.
cMultivariable model a priori including gender, community, age category as well as demographic/behavioural factors which were associated with
case/control status (i.e. whether CHiP was known to participant prior to PopART to home-visit, whether HIV status has been disclosed, whether
partner is HIV positive and on ART, and lifetime number of sexual partners).
dParticipants who did not have a test with CHiPs were those who self-reported known HIV-positive status, while those who had an HIV test with
CHiPs were likely to be previously undiagnosed.
ep-value for test for tend.
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Table 3. Participants’ perceptions of advantages and disadvantages of initiation of timely treatment
Controls
(achieved TLA)
N (%)
Cases
(did not achieve TLA)
N (%)
Odds
ratioa
LRTb p-value,
95% confidence
interval
Adjusted
odds ratioc
LRTb p-value,
95% confidence
interval
Individual level factors encouraging initiation of timely treatment (“Did any of the following encourage you start ART?”)
“For my health even though I don’t feel unwell”
N 96 (26) 127 (38) 1 <0.001 1 <0.001
Y 275 (74) 206 (62) 0.54 0.39 to 0.75 0.53 0.38 to 0.75
Recommended by HCW (CHiP/clinic staff)
N 35 (9) 55 (17) 1 0.005 1 0.02
Y 336 (91) 278 (83) 0.52 0.33 to 0.82 0.56 0.34 to 0.91
To protect partner from getting HIV
N 189 (51) 188 (56) 1 0.11 1 0.19
Y 182 (49) 145 (44) 0.78 0.58 to 1.06 0.81 0.58 to 1.12
“I know someone/others who are well on ART and want to be on it too”
N 142 (38) 155 (47) 1 0.01 1 0.08
Y 229 (62) 178 (53) 0.67 0.48 to 0.92 0.74 0.53 to 1.03
Individual level factors discouraging initiation of timely treatment (“Did any of the following discourage you from starting ART?”)
“I was worried someone would find out about my HIV because of taking treatment/going to the clinic”
N 278 (75) 232 (70) 1 0.1 1 0.15
Y 93 (25) 101 (30) 1.33 0.95 to 1.86 1.30 0.91 to 1.87
“I was/am not ready to take ART”
N 285 (77) 196 (59) 1 <0.001 1 <0.001
Y 86 (23) 137 (41) 2.42 1.73 to 3.38 2.25 1.58 to 3.21
“I don’t think the treatment works so there is no point in starting”
N 333 (90) 285 (86) 1 0.12 1 0.16
Y 38 (10) 48 (14) 1.44 0.91 to 2.29 1.42 0.87 to 2.30
“I don’t like the idea of taking life-long treatment”
N 288 (78) 234 (70) 1 0.03 1 0.05
Y 83 (22) 99 (30) 1.48 1.04 to 2.09 1.44 1.00 to 2.07
Stigmatizing attitudes which may affect initiation of timely treatment
“People living with or thought to be living with HIV are verbally insulted, harassed and/or threatened” ptrend 0.27
e
Strongly disagree 46 (12) 34 (10) 1 0.17 1 0.08
Disagree 76 (20) 83 (25) 1.47 0.85 to 2.53 1.64 0.92 to 2.92
Agree 137 (37) 133 (40) 1.28 0.76 to 2.15 1.30 0.76 to 2.23
Strongly agree 113 (30) 83 (25) 0.95 0.55 to 1.63 0.95 0.54 to 1.66
“I have felt ashamed because of my HIV status” ptrend 0.007
e
Strongly disagree 118 (32) 86 (26) 1 0.02 1 0.05
Disagree 139 (37) 106 (32) 1.10 0.74 to 1.64 1.20 0.78 to 1.84
Agree 59 (16) 74 (22) 1.83 1.12 to 2.98 1.82 1.10 to 3.03
Strongly agree 56 (15) 67 (20) 1.70 1.06 to 2.72 1.71 1.05 to 2.79
“I have been excluded from social gatherings or activities because I have HIV” ptrend 0.16
e
Strongly disagree 162 (44) 134 (40) 1 0.73 1 0.30
Disagree 187 (50) 177 (53) 1.14 0.82 to 1.59 1.31 0.94 to 1.89
Strongly agree/agree 23 (6) 22 (7) 1.13 0.59 to 2.16 1.40 0.71 to 2.76
ART, antiretroviral treatment; LRT, likelihood ratio testing.
Values in italics are p-values, values in bold (with or without italics) indicate statistically significant values.
aA priori adjusted for gender and community to reflect sampling strategy.
bLikelihood ratio test.
cMultivariable model a priori including gender, community, age category as well as demographic/behavioural factors which were associated with
case/control status (i.e. whether CHiP was known to participant prior to PopART to home-visit, whether HIV status has been disclosed, whether
partner is HIV positive and on ART, and lifetime number of sexual partners).
dThere were very few responses in the “strongly agree” and “agree” categories for this question, responses are therefore grouped as shown to be
more meaningful/increase power.
ep-value for test for trend.
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that it is pertinent to examine TLA to effect meaningful
change in ART coverage with a view to achieving the “second
90” of the UNAIDS 90-90-90 targets [18].
Our study found no evidence of associations between
demographic or socio-economic characteristics and TLA, simi-
lar to reported findings from other settings including one
which was in the context of UTT [8,11,12,14]. This is encour-
aging for a “universal” intervention that seeks to ensure high
coverage across the whole of the community. There are
emerging data however which show that men and young peo-
ple are less likely to initiate treatment even when diagnosed
with HIV [7,19]. The greater challenge appears to be the diffi-
culty contacting men and young people but once encountered,
these groups are not more likely to decline/defer treatment
initiation. Our study was not designed to examine gender dif-
ferences and we observed no association between age and
TLA. We focused on those who had been seen and referred
for treatment by the CHiPs and this may explain the lack of
association of age with TLA in our study population.
Having favourable views about the PopART CHiPs appears
to facilitate TLA with prior familiarity with the CHiPs (as fel-
low community members), feeling comfortable talking to the
CHiPs and accepting their advice, all encouraging TLA. Few
participants complained of healthcare worker factors as barri-
ers to linking-to-care. Clinic infrastructure factors however
were cited as disincentives (inconvenient clinic opening hours,
over-crowding, etc.). This is consistent with other research
which has shown that similar factors were associated with
increased loss-to-follow up among those who have engaged
with care [20].
While the evidence of associations was not strong we found
that behavioural factors, including self-reported sexual beha-
viour and HIV-related behaviour (namely disclosure of HIV
status) influenced TLA. Those reporting a greater number of
lifetime sexual partners were more likely to succeed with TLA.
This suggests that the self-acknowledged perception that one
might be at risk of HIV, facilitated linkage and ART initiation.
One possible explanation is that these individuals were more
willing to acknowledge living with HIV and hence achieved
TLA more readily. Consistent with this explanation is the find-
ing that those who reported “not feeling ready” or who said
they would only start treatment once they felt sick, were less
likely to achieve TLA. The finding that those with higher risk
behaviour are more actively engaging with UTT is encouraging
for treatment as prevention. The perception that treatment is
not indicated until someone feels unwell is important given
the persistent late presentation of patients for HIV care [21].
This is an important consideration to address in future health
promotion messaging.
Corroborating the findings of the study by Boyer et al. on
ART initiation (among those linked-to-care) in another UTT
trial, we found that disclosure of HIV-status facilitated TLA
[14]. Along a similar theme, participants who reported that
they had an HIV-positive partner on ART were more likely to
succeed with TLA themselves, while the opposite was true if
they had an HIV-positive partner who was not ART. Our data
also indicate that participants who reported that they had dis-
closed their HIV-positive status were more likely to report a
partner on ART than those who had not disclosed (36% vs.
17%, respectively p < 0.001). Protecting a partner from
acquiring HIV as a reason to start ART was not associated
with increased TLA (Table 3), and this may suggest that
greater efforts to promote a “treatment for prevention” mes-
sage are indicated.
The high proportion of men overall who had high AUDIT
scores is alarming (51%), although the prevalence in women
(20%) is also substantial. The difference in association of
alcohol excess with TLA by gender is interesting. Men with
high AUDIT scores were more likely to be cases, and this
suggests that provision of integrated alcohol reduction/treat-
ment and HIV prevention/treatment programmes that target
men should be explored. Among women, the evidence was
of a weak association in the opposite direction. A possible
explanation is that men with heavy alcohol consumption
avoided engagement with treatment and care, while women
with equivalent alcohol intake may have sought health-care/
treatment as a way to compensate for “unhealthy” beha-
viour. Furthermore, among women (but not men) a higher
proportion of those who were heavy drinkers considered
themselves at high risk of acquiring HIV infection compared
to those who were non-heavy drinkers (59% vs. 42%,
p = 0.005). This association among women is consistent with
our finding above that high risk perception may encourage
treatment engagement.
Our data indicate that stigma overall is not a major barrier
to TLA, but internalized stigma (i.e. taking on and believing to
be true, the negative beliefs and attitudes about PLWH) may
have an influence. This is said to be one of the most insidious
aspects of stigma, as it somehow makes PLWH feel “less
human” [22]. There is evidence to suggest that support groups
can help mitigate this form of stigma [23,24].
Our study had several limitations. Only participants who
agreed for the study research team to contact them could be
recruited into the study. This means that individuals who could
not be contacted, or declined or avoided contact would not be
represented in the study, nor would those who declined to con-
sent once contacted. While this is common to many community-
based survey studies, the representativeness of the study sam-
ple must be borne in mind as a limitation of the study. We did
see evidence of differential selection of potential participants by
case/control status with a higher proportion of randomly
selected potential controls recruited than randomly selected
potential cases (46% vs. 37%). As described earlier there were
also fewer men than women in the study sample despite fre-
quency matching on gender when randomly selecting the sam-
ple. Young people were also somewhat under-represented in
the final study sample. Both of these are likely due to the fact
that the study was conducted in the household and men and
younger people are less likely to be found at home than older
people. Reporting bias and social desirability bias are both pos-
sibilities, in common with most research using self-reported
data. However, given the wide range of themes explored by the
questionnaire and the lack of an obvious single hypothesis,
these biases are unlikely to be differential based on case or con-
trol status of the participant. Reverse causality must also be
borne in mind given that the CC study was conducted a period
of time after the referral for HIV care. Further, given the CC
design causality cannot be inferred from our findings and we
are limited to observing associations.
The strengths of this study have already been alluded to,
including the breadth and depth of the themes explored, the
novelty of examining TLA under UTT conditions and the focus
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on TLA as a combination of both timely linkage-to-care and ART
initiation, given that community-based testing is becoming
increasingly prevalent. In addition, we had a sizeable proportion
of men (approximately 40%) who are often under-represented.
Our study was conducted in large urban and peri-urban commu-
nities and this provides a good basis for generalizability for the
majority of those living with HIV in sub-Saharan Africa.
Further research is required to explain some of the results.
For instance, even though familiarity with the CHiPs encour-
aged TLA, there is a suggestion in our data that having an HIV
test with the CHiP was associated with being a case, that is,
failure to achieve TLA. This is most likely due to the fact that
those who tested with CHiPs were the ones receiving new
diagnoses of HIV infection, and needing time to become com-
fortable with the idea of needing treatment, whereas those
who did not test with CHiPs were the ones who already knew
their HIV-positive status and may have been more ready for
TLA. However, this warrants further enquiry. Emerging evi-
dence on the advantages of same-day initiation of ART upon
presentation at the clinic as a potential facilitator of TLA is a
theme which we did not explore, but this is an important topic
for future research [25].
5 | CONCLUSIONS
In summary, our study findings suggest that the universal
treatment intervention within PopART did not systematically
exclude any subsets of the population and it has the potential
to be universally acceptable. The finding that those who
reported having an HIV-positive partner not on ART were less
likely to achieve TLA points to the cumulative gains to be won
by initiating individuals on ART as it may have the added ben-
efit that their partner would be encouraged to do so as well.
As holding a favourable view of the CHiPs was associated
with successful TLA, we recommend investment in the cadre
of staff delivering services as a means to increase uptake. The
concerns expressed by participants about health-facilities war-
rants both on-going improvement of infrastructure and inno-
vative means to reduce the burden on clinics by providing
care in the community for patients who are stable and com-
fortable with non-clinic based care.
The findings that higher risk sexual behaviour may be asso-
ciated with more TLA holds great promise for the effective-
ness of UTT in achieving reductions in HIV-incidence at the
community level. Overall, we found few fundamental differ-
ences between those who linked-to-ART in a timely fashion
and those who did not, but the differences we did uncover
provide opportunities to achieve universal treatment coverage
within the framework of UTT.
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